scholarly journals Prognostic value of CD44v6 expression in breast cancer: a meta-analysis

2018 ◽  
Vol Volume 11 ◽  
pp. 5451-5457 ◽  
Author(s):  
Guang-Lei Qiao ◽  
Li-Na Song ◽  
Zhou-feng Deng ◽  
Ying Chen ◽  
Li-Jun Ma
Keyword(s):  
Breast Cancer ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Cd44v6 Expression

Prognostic value of endocrine treatment-related symptoms in patients with breast cancer: a meta-analysis

2016 ◽  
Vol 160 (2) ◽  
pp. 197-209
Author(s):  
Qiufan Zheng ◽  
Wen Xia ◽  
Qianyi Lu ◽  
Ruoxi Hong ◽  
Ge Qin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Endocrine Treatment

scholarly journals Prognostic Role and Clinical Significance of Tumor-Infiltrating Lymphocyte (TIL) and Programmed Death Ligand 1 (PD-L1) Expression in Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis Study

Diagnostics ◽  
2020 ◽  
Vol 10 (9) ◽  
pp. 704 ◽  
Author(s):  
Parisa Lotfinejad ◽  
Mohammad Asghari Jafarabadi ◽  
Mahdi Abdoli Shadbad ◽  
Tohid Kazemi ◽  
Fariba Pashazadeh ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Prognostic Value ◽  
Triple Negative ◽  
Meta Analysis ◽  
Disease Free Survival ◽  
Cochrane Library ◽  
P Value ◽  
Programmed Death Ligand 1 ◽  
Programmed Death

This meta-analysis aimed to evaluate the prognostic value of tumor-infiltrating lymphocytes (TILs) and programmed death-ligand 1 (PD-L1), their associations with the clinicopathological characteristics, and the association between their levels in patients with triple-negative breast cancer (TNBC). PubMed, EMBASE, Scopus, ProQuest, Web of Science, and Cochrane Library databases were searched to obtain the relevant papers. Seven studies with 1152 patients were included in this study. Like the level of TILs, there were no significant associations between PD-L1 expression and tumor size, tumor stage, lymph node metastasis, histological grade, and Ki67 (All p-values ≥ 0.05). Furthermore, there was no significant association between PD-L1 expression with overall survival (OS) and disease-free survival (DFS). In assessment of TILs and survival relationship, the results showed that a high level of TILs was associated with long-term OS (hazard ratios (HR) = 0.48, 95% CI: 0.30 to 0.77, p-value < 0.001) and DFS (HR = 0.53, 95% CI: 0.35 to 0.78, p-value < 0.001). The results displayed that tumoral PD-L1 expression was strongly associated with high levels of TILs in TNBC patients (OR = 8.34, 95% CI: 2.68 to 25.95, p-value < 0.001). In conclusion, the study has shown the prognostic value of TILs and a strong association between tumoral PD-L1 overexpression with TILs in TNBC patients.

scholarly journals Does dose-dense neoadjuvant chemotherapy have clinically significant prognostic value in breast cancer?: A meta-analysis of 3,724 patients

PLoS ONE ◽  
2020 ◽  
Vol 15 (5) ◽  
pp. e0234058
Author(s):  
Yuqin Ding ◽  
Kaijing Ding ◽  
Hongjian Yang ◽  
Xiangming He ◽  
Wenju Mo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Clinically Significant ◽  
Dose Dense

A Bayesian meta-analysis of the prognostic value of circulating HER2/neu levels in breast cancer (BC) patients.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 643-643
Author(s):  
Walter P. Carney ◽  
Robert Thiel ◽  
Dirk Bernhardt ◽  
Suhail M. Ali ◽  
Kim Leitzel ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Value ◽  
Current Knowledge ◽  
Early Stage ◽  
Dirichlet Distribution ◽  
Meta Analysis ◽  
Natural Extension ◽  
Progression Free Survival ◽  
Her 2 ◽  
Baseline Levels

643 Background: Many reports have shown the prognostic value of HER-2 measured in tumor tissue or in blood. In 2009, Finn et.al. showed that in a study of 579 MBC patients whose serum HER-2 levels (sHER-2) were constantly below normal had a longer PFS than patients with a sHER-2 level constantly above normal. Patients who converted from above normal to less than normal during therapy had a longer PFS than the opposite change. Methods: We performed a Bayesian meta-analysis of 12 studies where all sHER-2 levels were measured using an FDA cleared sHER-2 test with a standard cutoff of 15ng/ml. We chose a Bayesian approach because a “meta-analysis” is a natural extension of the Bayesian view that current knowledge is the result of prior knowledge modified by the data. After an in depth literature search, we selected 12 publications based on the following criteria. Baseline levels were available from either early stage or late stage patients who had at least a 2 year disease free or progression free survival as indicated by a Kaplan-Meier (K-M) curve. Results: The analysis included 4030 BC patients of which 1106 patients had baseline levels < 15ng/ml and 2924 patients had baseline values >15ng/ml. From the K-M curves, we estimated the number of recurrences up to 24 months in each group and prepared a 2x2 table for each study. We determined the odds ratio (OR) for the 12 studies which ranged from 0.57 to 74. A posterior distribution for the aggregated 12 studies can be represented by a Dirichlet distribution. 10,000 estimates of the aggregated OR indicated that there is a 95% credibility that the odds of a woman with baseline sHER-2 >15ng/ml recurring at or before two years is between 3.39 and 4.57 times higher than the odds of a woman whose baseline sHER-2 was < 15ng/ml recurring at or before two years. Conclusions: This meta-analysis agrees with previous studies that serum HER-2 levels > 15ng/ml can be a strong prognostic indicator for women with Breast Cancer and that managing therapy regimens to maximize the decrease in serum HER-2 levels could be important target in treating patients.

Sign in / Sign up

Export Citation Format

Share Document